Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/32890
Title: Potential of RAS inhibition to improve metabolic bone disorders
Authors: Gebru, Y
Diao, TY
Pan, H
Mukwaya, E
Zhang, Y
Issue Date: 2013
Publisher: Hindawi Publishing Corporation
Source: BioMed research international, 2013, v. 2013, 932691 How to cite?
Journal: BioMed research international 
Abstract: Metabolic bone disorder is usually caused by abnormalities of minerals and hormones metabolism. Recently, it has been proved by several studies that the renin-angiotensin system (RAS) in local bone tissue is directly involved in bone metabolism. Activation of skeletal RAS plays an important role in bone metabolic disorders. Based on in vitro, in vivo, and clinical studies, this review explains the roles of RAS in bone metabolism and also covers the potential approaches and beneficial effects of RAS inhibition on bone health. Differential strategies for inhibiting RAS can be employed to maintain bone health, which are attributed primarily to the reduced level of angiotensin II (AngII) and suppressed stimulation of the AngII signaling pathway. The use of renin inhibitors, angiotensin-converting enzyme inhibitors, and AngII receptor blockers either individually or in combination with each other could have promising results in fighting bone metabolic disorders associated with other cardiovascular diseases as well as independent bone injuries.
URI: http://hdl.handle.net/10397/32890
ISSN: 2314-6133
EISSN: 2314-6141
DOI: 10.1155/2013/932691
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

10
Last Week
0
Last month
0
Citations as of Oct 19, 2017

WEB OF SCIENCETM
Citations

7
Last Week
0
Last month
1
Citations as of Oct 15, 2017

Page view(s)

32
Last Week
4
Last month
Checked on Oct 16, 2017

Google ScholarTM

Check

Altmetric



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.